Actionable news
0
All posts from Actionable news
Actionable news in CBAY: CYMABAY THERAPEUTICS,

CymaBay Announces Pricing Of Public Offering Of Common Stock

NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $6.50 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by CymaBay. In addition, CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of common stock at the public offering price less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

The offering is expected to close on July 24, 2017, subject to the satisfaction of customary closing conditions.

Leerink Partners LLC, Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering. Oppenheimer & Co. Inc. and SunTrust Robinson Humphrey, Inc. are acting as co-lead managers for the offering.

The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A preliminary prospectus...


More